Gene: VAT1L

57687
-
vesicle amine transport 1 like
protein-coding
16q23.1
Ensembl:ENSG00000171724 Vega:OTTHUMG00000176845 UniprotKB:Q9HCJ6
NC_000016.10
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.269e-1 (AD)  5.587e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs8048150chr16:77812766 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RNF1280.841
NUDT100.833
SLC7A140.831
PEG100.825
NIPSNAP3B0.815
PRKAG20.814
HSDL10.814
UHMK10.813
MAP2K10.811
TUSC30.809

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MSX1-0.45
OR4F5-0.422
ASB4-0.416
TFAP2C-0.4
FOXJ1-0.391
WDR38-0.387
OR4F29-0.375
ZIC5-0.374
NXNL1-0.369
ACOX2-0.366

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAT1L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAT1L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAT1L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAT1L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAT1L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAT1L mRNA"27188386
D001280AtrazineAtrazine results in decreased expression of VAT1L mRNA25929836
C006780bisphenol Abisphenol A results in increased expression of VAT1L mRNA29275510
D002220CarbamazepineCarbamazepine affects the expression of VAT1L mRNA25979313
D002330CarmustineVAT1L mRNA affects the susceptibility to Carmustine16365179
D007631ChlordeconeVAT1L gene SNP affects the susceptibility to Chlordecone25622337
D003471CuprizoneCuprizone results in increased expression of VAT1L mRNA26577399
C014347decitabinedecitabine affects the expression of VAT1L mRNA23300844
D002945CisplatinCisplatin affects the expression of VAT1L mRNA23300844
D004026DieldrinDieldrin results in decreased expression of VAT1L mRNA28385952
C118739entinostatentinostat results in increased expression of VAT1L mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VAT1L mRNA"27188386
D017313FenretinideFenretinide results in decreased expression of VAT1L mRNA28973697
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of VAT1L mRNA26752646
D007854LeadLead affects the expression of VAT1L mRNA28903495
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of VAT1L mRNA28001369
D008767Methylmercury CompoundsMethylmercury Compounds results in increased expression of VAT1L protein26558463
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in increased expression of VAT1L protein26558463
C406082monomethylarsonous acidmonomethylarsonous acid results in increased expression of VAT1L protein24625837
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of VAT1L mRNA27935865
D010100OxygenOxygen deficiency results in increased expression of VAT1L mRNA26516004
C060836pioglitazone[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of VAT1L mRNA27935865
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of VAT1L mRNA23806026
C017947sodium arsenitesodium arsenite affects the methylation of VAT1L gene28589171
C047246temozolomideVAT1L mRNA affects the susceptibility to temozolomide16365179
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of VAT1L mRNA24680724
C009495titanium dioxidetitanium dioxide results in decreased expression of VAT1L mRNA23557971
D014212TretinoinTretinoin results in decreased expression of VAT1L mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAT1L mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of VAT1L mRNA24935251|2627250
C015559trimellitic anhydridetrimellitic anhydride results in increased expression of VAT1L mRNA19042947
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAT1L mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of VAT1L mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of VAT1L mRNA23179753|2627250
D014635Valproic AcidValproic Acid results in increased expression of VAT1L mRNA19101580|2317975

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI25416956  
GO:0008270zinc ion binding-IEA-  
GO:0016491oxidoreductase activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0055114oxidation-reduction process-IEA-  
GO ID GO Term Qualifier Evidence PubMed
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal